MedTrace Logo

Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse

NCT02679950 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2018-08-08

No results posted yet for this study

Summary

The current proposal is a pilot study. The Investigators plan to use next generation genome sequencing (NGGS) to define the molecular and genetic profiles of 3 cases of germ cell tumor (GCT) (with a component of yolk sac tumor) at the time of the initial diagnosis and 3 cases of late relapse GCT's, which are characterized by yolk sac tumor (and AFP secreting) predominant disease.

Investigators seek to demonstrate the feasibility of obtaining tissue biopsies (either archived or new biopsy) and utilization of NGGS in studying the molecular and genetic relationships between GCT's (with a component of yolk sac tumor) at the time of diagnosis and GCT's at the time of late relapse. This study will also provide preliminary information on genetic alterations, which may be a hypothesis for generating another study.

Conditions

  • Neoplasms, Germ Cell and Embryonal

Interventions

GENETIC

Next generation genome sequencing

DNA will be extracted from each sample and assayed.

Sponsors & Collaborators

  • Nasser Hanna

    lead OTHER

Principal Investigators

  • Nasser Hanna, MD · Indiana University School of Medicine, Indiana University Simon Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-20
Primary Completion
2017-04-25
Completion
2017-04-25

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02679950 on ClinicalTrials.gov